The FDA roadmap to reduce reliance on animal testing is accelerating interest in organ-on-chip systems, the article reports. In April 2025, the FDA signaled that animal testing should become the exception for preclinical safety and toxicity studies, supported by validated new approach methodologies (NAMs). The NIH added parallel requirements for funding notices to include human-focused approaches such as organ chips. Globally, the UK outlined a plan to phase out animal testing in research while accelerating alternative methods, increasing pressure on developers to produce regulators-ready evidence. The report highlights ongoing validation questions around standards and expectations for how NAM data will be reviewed in submissions. It also points to organ-chip use in aerospace research via the AVATAR investigation tied to Artemis II, reflecting a broader push for organ-chip adoption outside conventional lab settings.